Home>Topics>Stocks>Amicus Therapeutics

Amicus Therapeutics FOLD

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. GlaxoSmithKline ([[GSK]] -1.5%) and Amicus Therapeutics announce they have commenced testing to compare the safety and efficacy of Amigal in an 18-month study related to the treatment of Fabry ...

      Headlines

      Mon, 12 Sep 2011

      GlaxoSmithKline ( GSK -1.5% ) and Amicus Therapeutics announce they have commenced testing to compare the safety and efficacy of Amigal in an 18-month study related to the treatment of Fabry disease. Post your comment!

    2. Extraordinary medical coverage for an extraordinary CEO?

      Commentary

      Fri, 1 Jul 2011

      cure. By day, Crowley serves as CEO of Amicus Therapeutics ( FOLD ). Crowley also serves as an intelligence ..... on Wednesday, announcing his return to Amicus next month. Back in April, Amicus put out this release announcing that Crowley

    3. UPDATE 1- Amicus says US FDA removes clinical hold on Pompe drug

      Headlines

      Tue, 8 Mar 2011

      March 8 (Reuters) - Amicus Therapeutics Inc said U.S. health regulators removed the clinical hold on its treatment for Pompe disease and agreed to its plans to launch a new mid-stage study.

    4. Dropping Coverage of Amicus

      Commentary

      Tue, 29 Jun 2010

      We are no longer providing equity research on Amicus Therapeutics FOLD . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    5. New Morningstar Analyst Report - Amicus Therapeutics , Inc.

      Stock Reports

      Wed, 16 Jun 2010

      Shire's collaboration with Amicus also bodes poorly for Amigal ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders

    6. New Morningstar Analyst Report - Shire PLC

      Stock Reports

      Tue, 4 May 2010

      in 2008 of Dynepo ( from Transkaryotic Therapies ) after lackluster sales , and terminated a rare disease partnership with Amicus FOLD in 2009 following weak clinical data . While Adderall XR's generic competition is a drag on the top line , Vyvanse is experiencing

    7. New Morningstar Analyst Report - Shire PLC

      Stock Reports

      Fri, 5 Feb 2010

      in 2008 of Dynepo (from Transkaryotic Therapies) after lackluster sales, and terminated a rare disease partnership with Amicus FOLD in 2009 following weak clinical data.While Adderall XR's generic competition is a drag on the top line, Vyvanse is experiencing

    8. New Morningstar Analyst Report - Amicus Therapeutics , Inc.

      Stock Reports

      Wed, 27 Jan 2010

      Shire's collaboration with Amicus also bodes poorly for Amigal ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders

    9. A Banner Year for No-Moat Firms

      Headlines

      Sat, 26 Dec 2009

      Inc. ENER 1.61 -18.57 -57.4 Progenics Pharmaceuticals, Inc. PGNX 10.81 -18.88 -56.26 Amicus Therapeutics , Inc. FOLD 1.31 -61.28 -51.38 Citigroup, Inc. C -20.48 -28.17 -50.07 MetroPCS Communications, Inc

    10. Amicus Regains Control of Weakened Pipeline

      Commentary

      Fri, 30 Oct 2009

      value estimate in place following Amicus Therapeutics ' FOLD third-quarter results, despite ..... In conjunction with earnings, Amicus announced the termination of ..... clinical-stage drug candidates. Amicus regains international rights

    « Prev12Next »
    Content Partners